NSCLC is one of several tumors in which there are significant atypically upregulated expression levels of PD-L1 and PD-L2, yet the response to immunotherapy of NSCLC patients is about 30% (94). The gene discussed is PDCD1LG2; the disease is non-small cell lung carcinoma.